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ABSTRACT 
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POSSIBLE IMPLICATIONS FOR LENTIVIRAL DISEASE PROGRESSION  
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Sopitsuda Bunnag 
 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Professor Wail M. Hassan 
 
 
Lentiviral infections of humans and rhesus macaques result in acquired 
immunodeficiency almost invariably. Yet the duration between the initial infection and 
the onset of generalized failure of the immune system varies between subjects, in both 
organisms. Furthermore, acquiring the infection at an older age tends to accelerate 
disease progression, but mechanisms underlying the latter phenomenon have not been 
elucidated. It is widely accepted that the events that take place during the very early 
stages of infection play a critical role in determining disease progression. During this 
brief period, a fierce competition between viral virulence mechanisms and host immune 
defenses takes place. I hypothesize that critical immune responses, such as those 
associated with better outcome in primate lentiviral infections, are lost in rhesus 
macaques at older age. If true, the loss of these critical immune responses at the early, 
fate-determining stages of infection would explain rapid progression among those who 
acquire the infection at older age. Immunological parameters that have been associated 
with better outcome in primate lentiviral infections include multifunctional T lymphocyte 
responses, robust proliferative capacity, and production of interleukin 2 (IL-2) (16). 
Investigating how these immunological parameters change as the animals advance in age 
	   iii	  
may help us predict the possible mechanisms underlying rapid progression in older 
macaques, and by extension people.  
In this study, macaques of advanced age (21 – 29 years) were compared to young 
adult animals (3 – 7 years). I tested T cell qualities that have been linked to better 
outcome in primate lentiviral infections in the two age groups. Although most previous 
studies were based on studied carried out using infected animals, I tested uninfected 
animals. The rationale is that the observed divergence in infection outcome must have 
resulted from pre-infection, inherent differences between the two age groups. Post-
infection studies can help identify protective responses in an immunologically protected 
group, while pre-infection studies provide an opportunity to define intrinsic differences in 
an unaltered immune system that might have resulted in the divergent outcome after 
infection. Since in primate lentiviral infections the younger population is not protected 
(since the role is susceptibility in humans and macaques), I do not expect to identify a 
truly protective immune profile by examining post-infection responses. In fact, some of 
the potentially important responses can be masked by infection-induced impairments of 
the immune system. For this reason, I decided to focus this study on pre-infection 
qualities of T cells.  
Due to the large number of variables involved in the current study, I used 
principal components analysis (PCA) to identify the most discriminatory immunological 
parameters between the two age groups. PCA was used to enable the simultaneous 
evaluation of multiple parameters, which provides an advantage over univariate statistical 
analysis. Since PCA, as well as other multivariate methods, are scarcely used in 
immunology, which contributes to the novelty of this study. Here, I show that the 
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lentiviral-relevant immune responses, particularly on simian immunodeficiency virus 
(SIV) I have tested are generally more robust in younger animals compared to animals of 
advanced age. Younger animals produced more IL-2 in most of the T cell subsets upon 
both mass and antigen-specific stimulations. Moreover, higher frequencies of multiple 
cytokine producing cells were also observed in the young group, mainly in CD4+ T cell 
subsets upon mass stimulation and after exposure to certain antigen-specific stimulants. 
The data shows an indication of impaired T cell responses in older rhesus macaques that 
are likely to impact disease progression in primate lentiviral infections. I also show that 
immunological parameters such as the production of multiple cytokine producing CD4+ 
and CD8+ T cell subsets were the most important phenotypes in segregating the two age 
groups, highlighting the potential importance of these immunological qualities for 
protective immunity.   
This study should lay the grounds for the use of multivariate data analysis, 
particularly PCA, in immune profiling. This approach can potentially be applied to a 
wide variety of potentially critical areas in HIV or human immunodeficiency virus 
research, ranging from studying elite controllers to clinical trials, and from studying one 
arm or tissue of the immune system to studying multiple at once. Therefore, I hope this 
study will provide new insights to guide future research and ultimately contribute to our 
understanding of the correlates of immune protection in primate lentiviral infections, 
particular HIV infection.  
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Introduction 	  
Lentivirinae is a subfamily of retroviruses (family: Retroviridae) that includes the 
human immunodeficiency viruses (HIV-1 and HIV-2), as well as viruses that infect a 
variety of nonhuman primate. HIV-1 has been the cause of one of the worst pandemic 
known to mankind. Infection with lentiviruses typically results in a chronic, progressive 
disease due, in part, to virus ability to evade host immune mechanisms. HIV has the 
ability to undergo rapid mutations and the ability to target immune cells, mainly CD4+ T 
cells causing a decline in CD4+ cell counts and leaving the immune system in a 
destructed state (5). This will eventually lead to the terminal stage of the infection, which 
is known as acquired immunodeficiency syndrome (AIDS). HIV has been responsible for 
25 million deaths worldwide over the past three decades and more than 35 million people 
are currently living with the infection (5). Out of all people living with HIV, 97% reside 
in low- and middle-income countries, mainly in Sub-Saharan Africa (5). In the year 2008 
alone, 2 million people died due to HIV/AIDS, and an additional 2.7 million were newly 
infected (5). 
Even though a cure for HIV has not been defined, the severity of the disease can 
be overcome through the use of different therapies such as antiretroviral therapy (ART), 
including highly active antiretroviral therapy (HAART) regimens. These therapies are 
capable of reducing viral loads, extending life expectancy, and improving quality of life 
for HIV-infected persons. Yet, none of therapies currently available is curative. 
Therefore, the only intervention that can feasibly control the pandemic is the invention of 
a protective vaccine and this invention still remains as the ultimate goal of HIV/AIDS 
research.  
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Until today, a clear understanding of correlates of immune protection (COIP) 
needed for rational vaccine design is still not well defined. COIP is measurable 
immunological parameters that correlate with protection from the disease. The lethal 
course of HIV infection made experimental infections in humans unethical and 
unpractical, which puts a limit on the search for protective immunological parameters 
associated with this infection. Evidence has been gathered from past studies of humans 
with atypical disease progression. However, the identification of specific mechanisms 
underlying the acceleration of the disease progression is not well defined and this 
identification will likely provide new insights into the disease immunopathogenesis and 
immune protection. In HIV infection, protection is limited to a rare population of long-
term nonprogressors (LTNP) and elite controllers (Ec) who are able to control plasma 
viral loads to low and undetectable levels, respectively. There are many factors that may 
contribute to the rate of disease progression, including the patient’s age at initial 
infection, plasma viral loads at peak viremia during acute infection, viral set point, viral 
fitness, and the extent of immune activation. Both qualitative and quantitative 
impairments in immune function are caused by HIV infection. These impairments 
ultimately lead to an elevated risk of opportunistic infections at the terminal stage of the 
disease, or AIDS (5).  
Multiple disease progression patterns have been reported in rare populations of 
both humans and nonhuman primates, but due to the ethical issues of human trials, study 
of lentiviral infections in nonhuman primates is commonly practiced. Rhesus macaque 
(RM) or Macaca mulatta model has been researched extensively to understand simian 
immunodeficiency virus (SIV) and eventually HIV. The course of SIV infection in RM is 
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very similar to that of humans, which involves a sharp decline in SIV viral load during 
the acute infection while CD8+ T lymphocyte-mediated cytotoxic response to virus-
infected cells (6). Then a chronic phase follows, which is defined by the deletion of CD4+ 
T lymphocytes and eventually leading to the progression of AIDS-like illness or simian 
AIDS (SAIDS).  
In this study, I investigated the lentiviral-relevant aspects of the immune response 
that are associated with better outcomes of HIV/SIV in uninfected young adult and aged 
rhesus monkeys. Immunological parameters that are relevant to the disease protection 
have been widely researched. These parameters include, but may not be limited to the 
frequencies of multifunctional T cells, multifunctional T cell responses and high-level 
production of Interlukin-2 (IL-2) by T cells. I based my study on past findings with 
evidences that acquiring HIV infection in humans at 40 years of age or older increases 
the risk of rapid progression compared to those that acquired the infection at earlier adult 
age (7). I reasoned that the higher risk for rapid progression must have resulted from 
underlying pre-existing weaknesses associated with immunosenescence or the aging of 
the immune system. Therefore, the central hypothesis of this proposal is that the 
immunological parameters of T cells that are associated with better outcomes in primate 
lentiviral infections (i.e. HIV and SIV) are more pronounced in younger animals than 
they are in older animals since critical immune responses in primate lentiviral infections 
are expected to be lost in rhesus macaques at older age. 
Many studies have published data comparing immune responses that are 
associated with better outcomes of this disease in different groups of infected subjects. 
However, to the best of my knowledge the aspects of multiple immunological responses 
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of stimulated T-cells from uninfected rhesus macaques have not been directly compared 
in aged and young adult populations. This study of the unadulterated, pre-infection 
immune system will provide an opportunity to define intrinsic differences, which may 
offer some explanations for the divergent outcome after infection. Exploring lentiviral-
relevant immunological differences that distinguish between subjects with different 
progression patterns is likely to provide new insights into disease pathogenesis and 
provide more information to define COIP.  
  There are many parameters that can be used to evaluate relevant immune 
responses such as the multifunctionality, proliferative capacity, epitope recognition and 
more. I decided to peruse this research with the focus on the three cytokines IL-2, 
interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) produced by T cells 
in terms of frequency, absolute numbers, and mean fluorescence intensity (MFI).  The 
application of multivariate data analysis will enable the identification of immunological 
parameters that best discriminate between the young and old age groups. Since many 
variables are being tested in this study, the use of Principal Component Analysis (PCA) 
as the multivariate analysis is necessary. This method involves data reduction, which is 
used to condense multiple variables into fewer principal components (PC). PCs are 
ranked according to the amount of variance they explain. Although in PCA, the number 
of PCs that can be extracted from a dataset is equal to the number of measured variables, 
only the PCs that explain most of the data variance are retained. This enables the 
visualization of data points in terms of two or three PCs, instead of a large number of 
variables.  In other words, given a high dimensional (more than these parameters) data 
set, PCA enables plotting the data in two- or three-dimensional space based on the top 
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PCs, without losing much information. A powerful characteristic of PCA is that it does 
not take into account predefined groups, thus, all data-point groups visualized on PC 
plots are formed naturally (i.e. solely based on the data without any optimization). 
Finally, once groups are identified on the plots, the contribution of the original variables 
to each PC can be found, which can be used to identify the most discriminatory variables.   
In the remainder of the background section, I will summarize immune alterations 
linked to immunosenescence in humans and nonhuman primates and aspects of the 
immune response that have been linked to better outcome in lentiviral infections.  
Immune dysfunction and aging 	  
The negative impacts that aging has on the performance of the immune system is 
believed to be influenced by chronic exposure and interactions with foreign antigens, 
environmental changes and stress (17). As the function of the immune system declines, 
the susceptibility to viral and bacterial infections will intensify (18). Multiple lines of 
evidence from research done in the 1960s suggested that changes in the T-cell 
compartment are the main contributors to the age-dependent decline in immune function. 
T-cell functions are found to be altered due to aging include T-cell receptor (TCR) 
signaling, response to vaccines, cell proliferation, and cytokine production. Deterioration 
of T-cell function may result in reduced activation and cytokine secretion, specifically the 
secretion of IL-2 from memory T-cells (18). Decreased IL-2 secretion contributes to the 
reduction of T-B cell interactions, which may lead to an impaired humoral immune 
response (1).  
Age-related thymic involution, which might be the result of hormonal changes, 
also contributes to a decline in the production of functional T cells. Studies have shown 
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that the growth of the thymus is terminated after puberty and by that period the thymus 
will weigh about 25-30 grams (19). In a healthy person, the rate of thymus tissue loss is 
approximately 1% per year (19).  
Multiple reports provided evidence in support of the clear role of diminished 
CD4+ and CD8+ T cell numbers in age-dependent immune dysfunction (20). The 
observation that the relative abundance of naïve and memory T cells is preserved until 
age 65 years led to the hypothesis that naïve T-cells in adults are generated by 
proliferation of existing cells, and not from maturation in the thymus (20, 21).  It has also 
been shown that the diversity of naïve and memory T-cells remained constant up to age 
65 and will start to decline between 65 and 70 years of age (20). Non-human primates 
such as Rhesus macaques also experience a greater morbidity and mortality from 
infectious diseases due to the advancement of age (23). T cell subsets in RM resemble 
those in humans, which includes naïve (N), effector cells (EC), central memory (CM) and 
effector memory (EM). These subsets can be distinguished according to the expression of 
surface markers similar to humans. As aging progresses, RM experience the loss of naïve 
T cells due to a combination of different age related changes in T cell activities such as 
the decrease in hematopoietic stem cell in bone marrow, decrease in T cell migration to 
the thymus and the accelerated conversion of naïve T cells to memory T cells (23). The 
decrease in the ratio of CD4+ and CD8+ is another hallmark of immunosenescence in RM. 
This is due to the negative correlation between age and CD8+ T cells and the positive 
correlation between CD4+ T cells and aging (23). Aged populations in both humans and 
monkeys are, therefore, more prone to infections and tend to take longer to recover from 
them.  
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Aspects of T lymphocyte immune responses with relevance to HIV disease outcome 	  
Innate immunity is very crucial in the initiation of adaptive immune responses, 
which can be further divided into cell-mediated and humoral immune responses 
involving T-lymphocytes and B-lymphocytes, respectively. T-lymphocytes are classified 
into smaller subpopulations of CD4 helper T cells and CD8 cytotoxic T cells 
differentiated by molecular markers and functionalities. T-cell development takes place 
exclusively in the thymus. As CD4 and CD8 T cells mature they leave the thymus and 
enter secondary lymphoid organs where they recognize their cognate antigen in the 
context of major histocompatibility complex (MHC) class II and class I molecules on 
antigen-presenting cells. Following antigen exposure, CD4+ and CD8+ T cells undergo 
differentiation thorough various stages. Starting from naïve cells, they proliferate and 
differentiate to form memory cells under the influence of certain cytokines (12). 
Protective memory is mediated by effector memory T cells that migrate to inflamed 
peripheral tissues and display immediate effector function, whereas reactive memory is 
mediated by central memory T cells which have little or no effector function, but can 
proliferate and differentiate to effector cells in response to antigenic stimulation. As naive 
T cells differentiate into memory and effector T cells they acquire the ability to 
proliferate in response to homeostatic signals. Central memory T cells produce mainly 
IL-2, but after further antigenic stimulations, they will produce large amounts of IFN-γ. 
Effecter memory cells however, display characteristic sets of adhesion molecules that are 
required for homing to inflamed tissues and are characterized by rapid effector function 
through the production of IFN-γ (13). Memory T cells may survive for a long time in 
lymphoid organs and peripheral tissues. They are easily activated and can perform 
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immediate effector functions or undergo activation and clonal expansion in lymphoid 
organs to mount a secondary immune response if interacted with the same antigen in the 
future (13). There are many factors that can affect the magnitude T cell activation such as 
concentration of an antigenic peptide, affinity of TCR toward the antigen, and 
inflammatory stimuli. Unlike memory T cells, most effector T cells will disappear after 
the antigenic agent is eliminated. Effector T cells differentiate into two major subtypes of 
cells known as Th1 and Th2 cells, which have the ability to generate different types of 
cytokines. However the main cytokines produced by effector T cells are IFN-γ, IL-2, and 
TNF-α. 
Most of the cytokine secretions by T-cells are correlated with the rate of viral 
replication in terms in HIV/SIV infection (24) and research evidences show that the role 
of CD8+ T-cells is crucial in controlling HIV/SIV replication, including the frequency of 
replication, epitope recognition and functional quality (25). Studies showed that HIV 
infected LTNP possess HIV-specific CD8+ T-cell responses with enhanced functionality 
through the measurement of five specific CD8+ T-cell responses (degranulation, IFN-γ, 
M1Pb, TNF-α and IL-2 secretions) (25). These HIV specific CD8+ T-cells are equipped 
with unique functional patterns with different profiles between LTNP and rapid 
progressors. HIV specific CD8+ T-cells in LTNP have the capacity to produce TNF-α and 
IL-2 and at the same time maintaining other functions which give the cells characteristics 
of multifunctionality. However the expression of HIV specific CD8+ T-cells responses in 
rapid progressors are limited to IFN-γ with low production of TNF-α and even less IL-2 
(25). Moreover, LTNP are also known to have the ability to maintain a healthy level of 
multifunctional HIV specific CD4+ T cells when compared to rapid progressors (25). The 
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low maintenance of CD4+ T-cells along with HIV specific CD8+ T-cells in the 
progressors helps explain why little improvement is observed during an initial treatment 
due to the limited HIV specific CD4+ T-cell pool. During the early course of infection, 
HIV specific CD4+ T-cell responses are impaired and this is a hallmark of the progressive 
course of infection (26). However, in Ec subjects, the proliferative capacity of HIV 
specific CD4+ T-cells is well maintained (27). They are able to produce more IL-2 in 
cohort with other functions giving them polyfunctional quality. The progression of AIDS 
can be measured by assessing the “Quality of CD4+ T-cell responses” during infection 
(16). This quality is defined by the ability of a T cell to produce multiple functional 
molecules, such as cytokines and enzymes, which led to describing these cells as 
multifunctional T cells (16). One of the most important aspects of characterizing the 
potential of T cells is the observation of the magnitude of T cell responses. These 
responses can be represented by the frequency of specific effector functions such as the 
secretion of cytokines through the antigen specific stimulation. T cells as a whole, display 
high heterogeneity and are capable of eliciting a wide range of functions including, the 
ability to proliferate, organize immune responses by chemo-attractant secretions, 
eradicate infected cells via cytokine production and many more. Because of the 
characteristic of the heterogeneity, certain subset of T cells can be protective against 
certain diseases. This can be presume that the most effective protective immune response 
from T cells against any infections comes from a certain subset that are expressing a 
unique combination of functions. The combination of these functions can be defined as 
“The quality of T cells”. Series of recent studies have shown that better quality of T cells 
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is critical in mounting a protective immune response and has been shown to correlate 
with disease non-progression. 
Cytokine secretions are commonly measure upon stimulation of T cells in order to 
predict T cell quality. The secretion of IFN-γ has been extensively used as a parameter to 
assess cellular immune response against infections through its role in clearance of many 
infectious agents. IFN-γ is known as a “canonical” cytokine of Th1 response and it is 
responsible for the clearance of bacterial, viral and fungal infections (15). However, some 
studies have shown that the assessment of IFN-γ secretion alone is not enough to define 
the correlate of immune protection. This is when the measurement of TNF-α is added to 
the study for a more accurate analysis of an enhanced protective immune response (16). 
TNF-α is able to aide in the killing of intracellular bacteria, viruses and parasites. The last 
cytokine to be included in the study for the analysis of T cell quality is IL-2, which plays 
a main role in promoting the expansion of CD4+ and CD8+ T-cells, rendering the 
amplification of the effector T cells (15). IL-2 also has the capability to enhance CD8+ T 
cells memory capacity and effector functions (16). These three cytokines are commonly 
used to identify the immune responses elicited by T cells against infections that challenge 
the T cells such as HIV/SIV. Ferre et al showed that HIV-Gag specific CD4+ T cell 
responses (which can be measured by the production of IFN-γ, TNF-α and IL-2) were 
well maintained in subjects with on going antiretroviral therapy (ART) (27). HIV CD4+  
specific epitopes are also believed to play important roles in the progression of HIV. 
Studies from Vingerts et al demonstrated that HIV specific CD4+ T-cells in Ec have 
higher functional avidity upon the observation of the strong responses of HIV-Gag p24 
peptide with multiple HLA class II alleles. Studies concluded with subjects with 
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abundant HLA class II (B27 and B57) alleles are capable of producing robust HIV 
specific CD4+  T-cell responses as well as maintaining polyfunctional CD4+  T-cells (27). 
However, further studies must be performed to determine a clear linkage between HLA 
alleles and HIV specific CD4+  T-cells as well as HIV specific CD8+  T-cells. 
In order to have a clear understanding of the immune responses and the quality of 
T cells, each subset of CD4+ and CD8+ were examined in this study, which include, naïve 
cells, effector cells, central memory cells and effector memory cells. Both CD4+ and 
CD8+ T cells have the ability to differentiate and proliferate into memory cells and 
effector cells upon contact with specific antigen. Two main populations of memory T 
cells exist; central memory (CM) and effector memory cells (EM). CM cells screen for 
the presence of specific antigens, are concentrated in lymphoid tissues, and secrete large 
amount of IL-2. EM cells act as the first line of defense in the peripheral tissues and 
mainly produce effector cytokines such as IFN-γ and TNF-α (15). In HIV infection, a 
rapid loss of CD4+ T cells is one of the hallmarks of the infection, which is frequently 
accompanied by chronic immune activation. The latter has been shown to associate with 
faster disease progression (33). 
The subsets of T-cells can be classified based on the molecules presented on the 
surface (surface markers). These markers are often used to associate cells with certain 
immune functions. Examples of the a few markers that are essential markers for the study 
of T cell compartment include CD3, CD4 , CD8, CD28, CD40, CD45RA, CCR4, CCR7, 
CXCR3, CXCR4 and many more. However, this study will base the classification of T-
cell subsets on the constructed panel for the staining of surface markers, which includes, 
CD3, CD4, CD45RA, and CCR7. CD3 is a common marker for distinguishing T cells 
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from other cells and it is a part of T cell receptor complex. CD4 is a T helper cell lineage 
marker, which is the initiator of an early phase of T cell activation. CD45RA is expressed 
on naïve T cells, as well as the effector cells in both CD4+ and CD8+  T cells (14). 
However, with an increase in the antigen experience, the expression of CD45RA will be 
lost. Central and effector memory T cells will gain the expression of CD45RO instead 
(15). The expression of CCR7 aide in the differentiation between T cells with effector 
function that can migrate to inflamed tissues and T cells that requires secondary stimulus 
prior to the acquisition of the effector functions. A clear understanding of immunologic 
memory is very critical for the study of vaccine development, infectious disease, and 
immune reconstitution (14).  
Hypothesis and specific aims 	  
Since age was shown to influence disease progression in HIV infection, there is a 
possibility that there might be underlying age-dependent immunological alterations to 
explain this phenomenon of accelerated disease progression in the older population. 
However, clear descriptions of age-dependent alterations and mechanisms underlying 
these immunological parameters in rhesus macaques have not been reported.  
I hypothesize that critical immune responses or the immunological phenotypes, 
such as those associated with better outcome in primate lentiviral infections, are lost in 
rhesus macaques at older age. Those critical immune responses associated with better 
outcome in primate lentiviral infections include multifunctional T cells, high IL-2 
secretion, and high proliferative capacity (16). It is well established that the early events 
that take place early during acute infection play a crucial role in determining the course 
of lentiviral infections in primates. This work would provide initial evidence to explain 
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age-dependent differences in progression patterns and define the immunological 
parameters that distinguish between the two age groups. These results would also be 
beneficial in planning of future experiments using the most popular primate model in 
HIV/AIDS research (the rhesus macaque). More over, this will provide researchers with 
information to help them choose proper age groups to include in their experiments as well 
as contributing to the understanding of the correlates of immune protection in primate 
lentiviral infections.  
 
Specific aim 1. Identification of potential differences in T-cell cytokine production 
patterns in aged and young rhesus macaques after mass stimulation: 
a. Comparing the patterns of IL-2, IFN-γ, and TNF-α secretion, including the 
frequencies of single cytokine-producing cells and multifunctional cells, after 
staphylococcal enterotoxin B (SEB) stimulation and phorbol myristate acetate and 
ionomycin (PMA/I) stimulations. SEB stimulates a large number of cells via the 
T-cell receptor, while in the case of PMA/I, masses of T cells are stimulated by 
activating protein kinase C and inducing calcium release, while bypassing the T-
cell receptor altogether. This will allow the examination of large numbers of cells 
and will address the potential of T cells regardless of their T cell receptor 
specificity. 
b. Comparing the expression level of the different cytokines in the two age groups 
after mass stimulation. Mean fluorescence intensity (MFI) will be used as a 
measure of expression by individual cells, and will be compared between the two 
age groups for all three cytokines. 
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c. Multivariate data analysis will be used to identify the most important parameters 
in discriminating between the two age groups. I will use principal component 
analysis (PCA) for this purpose. PCA is used to reduce the number of variables 
into fewer principal components (PC) and identifies the PCs and variables that 
contribute the most to the variance in a data set.   
 
Specific aim 2. Identification of potential differences in T-cell cytokine production 
patterns in aged and young rhesus macaques after antigen-specific stimulation:  
a. Comparing cytokine production patterns as mentioned above, but after stimulation 
with SIV envelop and Gag peptides and Cytomegalovirus (CMV) peptides. Cell 
frequencies, absolute numbers and MFI will be studied.  
b. Multivariate data analysis will be used to identify the most discriminating 
parameters as discussed under the previous specific aim.  
 
Specific aim 3. Comparing CD4+  and CD8+  T cell proliferative capacity in aged and 
young rhesus macaques.  
a. Comparing the proliferative capacity of T cells after Anti-CD3, SIVgag and CMV 
peptides stimulation, using Ki-67 antibody staining. Ki-67 stains actively 
proliferating cells and, thus, the frequency of Ki-67 positive cells is commonly 
used to evaluate the proliferative capacity of immune cells.  
Materials and methods 	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Flow cytometry 
Reagents 	  
PMA and I were purchased from Sigma-Aldrich, St. Louise, MO;  staphylococcal 
enterotoxin B (SEB) from Toxin Technology, Inc., Sarasota, FL; purified, unconjugated 
anti-CD3, anti-CD3 (PerCp.Cy5.5), anti-CD4  (PE.CF594), anti-CD8 (PE.Cy5), anti-
CD14 (PE), anti-CD20 (BV605), anti-CCR7 (PE), anti-CD95 (PE), anti-IL-2 (FITC), anti-
IFN-γ (APC), anti-TNF-α (PE.Cy7), anti-IL-2 (FITC), anti-TNF-α (PE.Cy7), anti-IFN-γ 
(APC), and anti-Ki-67 (PE.Cy7)  from BD Biosciences, Franklin Lakes, NJ; anti-CD28 
and anti-CD49d from Biolegend, San Diego, CA; and Violet LIVE/DEAD fixable dead 
cell staining kit from Lifetechnologies, Carlsbad, CA. SIV mac239 Env peptide set (6883), 
SIV mac239 Gag peptide set (6204), and HCMV pp65 peptide set (12014) were obtained 
through the NIH AIDS Reagent program, division of AIDS, NIAID, NIH. 	  
Whole blood samples were collected from rhesus macaques housed at the 
Wisconsin National Primate Research Center (Madison, WI). Animal care and sample 
collection were done in accordance with the University of Wisconsin Institutional Animal 
Care and Use Committee guidelines and the NIH  “Guide to the Care and Use of 
Laboratory Animals.” Blood mononuclear cells (PBMC) were purified using gradient 
centrifugation and were stored in liquid nitrogen until used. Prior to experiments, frozen 
PBMCwere thawed in a 37°C water bath and washed with RPMI 1640 to remove 
freezing medium. Additionally, cells were revived by incubation in growth medium 
(RPMI 1640 containing 10% FBS, 100 IU/mL penicillin, and 100 µg/mL streptomycin) 
at 37°C in 5% carbon dioxide atmosphere for 18 hours.  	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In vitro stimulation 	  
Incubated revived cells were harvested and centrifuge at 350 xg for 5 minutes. 
After discarding the supernatant, cells were treated with phorbol myristate acetate and 
Ionomycin (PMA/I) or cell stimulation with the final concentration of 50 ng/mL and 500 
ng/mL respectively. SEB were use to stimulate the cells with the total of 10ug of SEB. A 
total of 2.5 ug of SIV antigen and peptide were used to stimulate PBMC. Env peptides 
matching SIVmac239 sequence were used to stimulate T lymphocytes through their antigen 
receptors and super antigen, SEB, was used to stimulate large number of cells.  The 
stimulated cells were be incubated for 12-15 hours. A total of 2.5% of Brefeldin A 
(GolgiPlug™) was added 1 hour after stimulation.  Brefeldin A is a fungal metabolite, 
which can interfere with protein secretion and inhibit protein transport from the 
endoplasmic reticulum to the Golgi apparatus upon incubation.  It has the ability of 
enhancing intracellular cytokine staining signals by blocking the transport processes 
during cell activation. However, cells were incubated up to 12 days with Anti-CD3, 
SIVgag and CMV peptides for the detection of Ki-67 expression and the medium and 
stimulants were replenished on day 7 of the incubation. Cells were washed with 
Wash/Stain after incubation via centrifugation at 350 xg for 5 minutes and removing the 
supernatant and are then ready to be tested for surface markers of interest.  
Staining for flow cytometry 	  
Cells were stained with appropriately titrated fluorescently labeled monoclonal 
antibodies. Violet LIVE/DEAD staining antibodies were diluted in 1:1000 dilutions with 
PBS. Cells were first stained with 0.1 uL of violet LIVE/DEAD fixable dead cell staining 
kit (Lifetechnologies) followed by antibody staining for surface markers and intracellular 
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staining markers. Staining of cells took place in a dark for 20 minutes at room 
temperature. Cells were washed with 1 mL of Wash/Stain and centrifuged at 350 xg for 5 
minutes. Prior to intracellular staining, cells were fixed and washed twice. Cells were 
then resuspended in 1 mL of PBS and the data were analyzed by flow cytometry using 
the appropriate excitation and detection channel 
Data collection 	  
 Flow cytometry data were collected using a BD FACSAria III cytometer. Flow 
cytometry data were analyzed using FlowJo (Treestar, Inc., Ashland, OR). Multivariate 
data analysis was done using Bionumerics (Applied Maths, Austin, TX). To facilitate 
studying a data set characterized by a large number of variables, PCA reduces the number 
of variables by condensing them into fewer PCs. PCs are ranked according to their 
contribution to the variance in the data set. The PC with the largest contribution to data 
variance is the most discriminative PC. PCs can be ranked according to their contribution 
to variance and then plotted into two- or three-dimensional graphs. The contribution of 
each variable to each PC can then be examined to identify the most discriminative 
variables. I will use this method to identify the immunological parameters that best 
discriminate between young and aged RM monkeys.    
Methods of flow cytometry	  
Controls and panel development 
Compensation with ArC™ cmine reactive beads  
 
In multi-color flow cytometry, more than 6 (often 8 or more) colors are used to 
label different proteins in the cell. Each one of the color is read by a dedicated channel 
and a detector/photomultiplier tube (PMT) assembly. With many colors used, some of the 
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channels may overlap with neighboring channels and, therefore, inaccurately contribute 
to the readings taken at these channels. For this reason, compensation controls are 
included in every run. Compensation controls are samples (cells or beads) stained with 
single color, each of which will read at all channels used in the run. This will enable the 
investigator to generate a record of the erroneous contribution of each color to all 
channels in the panel other than its own. These erroneous signals are then subtracted 
electronically from the readings obtained using all samples. The ArC™ Amine Reactive 
Compensation Bead Kit (Lifetechnologies) contains the ArC™ reactive beads and the 
ArC™ negative beads. The incubation with any reactive dye will provide distinct positive 
and negative populations of beads and this information can be used to setup the 
compensation. A drop of ArC™ reactive beads is added into appropriately labeled tubes. 
Prepared fluorescent monoclonal antibodies were added to the corresponding amount of 
antibodies (same as those used to treat cells) into the ArC™ reactive beads. Beads were 
incubated for 30 minutes at room temperature away from light. After incubation beads 
were centrifuged for 5 minutes at 300 xg with 1mL of PBS or buffer. Supernatant were 
carefully removed and bead pellets were suspended with 0.5 mL of staining buffer. One 
drop of corresponding ArC™ negative beads was added to each labeled tube. The tubes 
were well vortexed prior to the analysis by flow cytometey. 
Fluorescence minus one control 	  
 In this study, multi-parametric flow cytometry was used. This technology 
involves the simultaneous use of multiple fluorophores, some of which may have 
partially overlapping emission spectra. This inherent difficulty in the technology is 
routinely overcome by performing compensation controls. Compensation controls are 
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composed of samples each stained with one antibody, in addition to an unstained control. 
These samples are used to calibrate the cytometer by defining the background 
fluorescence in each of the channels used in a given experiment (using the unstained 
control) and the bleed through from each channel into all others, if any. This makes it 
possible to electronically subtract the bleed through from the reading taken later for the 
actual samples. Fluorescence Minus One control (FMO) is a type of control in which 
samples are stained with panels identical to the experimental panel, except that each is 
missing a single conjugated antibody. This enables the operator to monitor the amount of 
bleed through into the missing color, as well as the effect of removing each of the color 
one at a time on all other colors. After electronic compensation, both types of effects 
should be negligible for all colors in the panel.  
Antibody titration 
 
 The titration of antibodies is one of the most critical steps to ensure that the data 
acquired are accurate with a precise concentration of antibody. The overuse of antibody 
may cause an increase in the background, which will reduce the ability to distinguish the 
positive population. However, the low amount of antibody will also decrease the positive 
signals.  A precise amount of antibody will yield the optimal separation between positive 
and negative populations as well as allowing minimum increase in background 
fluorescence from the flow cytometer as well as limiting a signiﬁcant degree of 
nonspeciﬁc binding. The issue with nonspecific antibody binding can lead to an 
inaccuracy in the data. Nonspeciﬁc antibody binding is expected to occur when the total 
number of antibody molecules greatly exceeds the number of target antigens and this may 
occur in both positive and negative population of the cells.  
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Gating strategies 	  The application of optimal gating was used to achieve accurate results of cell 
assessment. Many factors needed to be considered and incorporated into the gating 
strategy to yield accurate results and these factors include, exclusion of debris, exclusion 
of dead cell, utilization of negative controls, and utilization of appropriate concentration 
of staining markers. Forward scatter (FSC) and side scatter (SSC) were used to eliminate 
any debris and non lymphocytes. LIVE/DEAD® Fixable Dead Cell Stain kit was used to 
distinguish between viable and non-viable cells. Live/Dead fluorescence and side scatter 
(SSC) were used to eliminate the non-viable cells. Once the non-viable cells and debris 
have been eliminated, further specific analysis can be carried out by selecting specific 
fluorescence markers that were tagged in the cells.  
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Figure 1 Gating strategy for the analysis by FlowJo: The steps of gating identifies unique functional 
subsets of CD4+ and CD8+  T cells as well as the cytokine secretions based on the fluorescence 
staining of live cells and on the expression of other markers, such as CD3, CD4+ , CD8+ , CD4+ 5RA, 
CCR7, IFN-γ , IL-2, and TNFα 
 
Results 
1. Younger rhesus macaques showed greater T cell responses after mass 
stimulation with PMA/I or SEB 
 
1a. Percentage of cytokine production from CD4+ and CD8+ T cell subsets: 
 	   The activation or the stimulation of cells plays a critical role in the pathogenesis 
of many diseases. Studies in the past had demonstrated a growing consensus that a 
generalized T-cell activation plays a central role in the pathogenesis of HIV/AIDS 
involving the rate of disease progression. Moreover, acquiring HIV infection in humans 
at 40 years of age or older increases the risk of rapid progression compared to acquiring 
the infection at earlier adult age (7). To investigate and compare the potential of T cells 
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between two age groups (young and old) regardless of their specificity and explore the 
parameters that are known to be related to better outcomes in HIV/SIV infection, I 
stimulated PMBC from 10 young and 10 old RM with PMA/I or SEB. The analysis of the 
pattern of cytokine production upon PMA/I will provide information about the overall 
potential of the cells in un-altered immune system of pre-infected RM regardless of the T 
cell receptor specificity because PMA/I have the ability to stimulate T cells by bypassing 
the T-cell receptor altogether. But SEB has the ability to stimulated mass of T cells 
through the interaction with T cell receptors. So the immune responses seen upon SEB 
stimulation will move towards a more realistic process of the immune activation by going 
through the interaction with T-cell receptors. However SEB stimulated immune response 
is still considered to be non-specific.  
I assessed the percentages and absolute numbers of the cytokine producing cells, 
as well as the mean fluorescence intensity (MFI) of each cytokine. Boolean gating 
analysis was used to analyze the multifunctional cells by observing the cytokine 
production in various combinations. The subsets of both CD4+  and CD8+  including 
naïve cells, effector cells, central memory cells and effector memory cells, were 
classified by the surface markers of CCR7 and CD45RA as mentioned in the method 
section. The results were evaluated by measuring the frequency of the cytokine producing 
cells after the subtraction of background fluorescence. Control samples, which were the 
un-stimulated cells, provided values for background fluorescence.  
 As shown in Figure 1A a significant difference was observed in the percentage of 
multifunctional effector CD4+  T cell producing IL-2 and TNF-α when compared between 
the young and the old with a higher percentage of multifunctional CD4+  effector T cells 
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in the younger population. However no significant differences were found between the 
two age groups in other cytokine combinations after PMA/I stimulation. Figure 1B is 
shown for the purpose of comparison between the two stimuli of the same subset of CD4+  
under the same condition but with SEB stimulation, however no significant differences 
were found in the multifunctional CD4+  effector cells upon SEB stimulation (Figure 1B).  
In Figure 2A, significant differences (*P-value < 0.05) between two age groups 
were observed in each of the percentage of single cytokine producing central memory 
CD4+ T-cells (IFN-γ , IL-2, and TNF-α) after PMA/I stimulation. The percentages of 
multifunctional CM CD4+ T-cell (IFN-γ+ TNF-α+) between the two groups was 
significantly higher in the young. No significant differences were shown in SEB 
stimulated group (Figure 2B and 2D).  
The percentage of IL-2 producing effector memory (EM) CD4+  T-cells are both 
significantly higher in the young population in both PMA/I (Figure 3A) and SEB 
stimulation (Figure 3B) with *P-value <0.05 and *** P-value < 0.000, respectively. 
Conversely, the percentage of multifunctional EM CD4+ T cells (IL-2+ TNF-α+) was 
significantly higher in the young upon SEB stimulation (Figure 3D). The same pattern of 
significance was observed in the percentage of IL-2 secretion by CD8+ effector cells that 
were stimulated by SEB (Figure 4B) and CD8+  CM cells upon PMA/I stimulation 
(Figure 5A). No significant differences were observed in the rest of the subsets and the 
frequencies of cytokine production (not shown).  
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Figure 2 Percentages of multifunctional CD4+ effector cells cytokine production. (A) Percentage of 
multifunctional CD4+ effector cells after PMA/I stimulation PBMC of 10 young and 10 old RM were 
stimulated with PMA/I and they stained with specific fluorescence markers to indicate the subsets 
and the cytokine production (B) Percentage of multifunctional CD4+ effector cells after SEB 
stimulation PBMC of 10 young and 10 old RM were stimulated with SEB. Data are presented as the 
percentages of multifunctional CD4+ effector T cells. Multifunctional cells are classified as cells that 
are capable of producing more than one cytokine at a time. 
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Figure 3 Percentages of cytokine production in central memory (CM) CD4+ T-cell and 
multifunctional central memory CD4+ T-cell. (A) Percentage of cytokine secretion from CM CD4+ 
after PMA/I stimulation.  (B) Percentage of cytokine secretion from CM CD4+ T cells after SEB 
stimulation. (C) Percentage of multifunctional CM CD4+ T cells after PMA/I stimulation. (D) 
Percentage of multifunctional CM CD4+ T cells after SEB stimulation 
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Figure 4 Percentages of cytokine production in effector memory (EM) CD4+ T-cell and 
multifunctional EM CD4+  T-cell. (A) Percentage of cytokine secretion from CM CD4+ T cells after 
PMA/I stimulation.  (B) Percentage of cytokine secretion from EM CD4+ T cells after SEB 
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stimulation. (C) Percentage of multifunctional EM CD4+  T cells after PMA/I stimulation. (D) 
Percentage of multifunctional EM CD4+  T cells after SEB stimulation 
 
	     	  	  	  	  	  	  	  	  	  	  	  
	   	  
Figure 5 Percentages of cytokine production in effector CD8+ T-cells.  (A) Percentages of cytokine 
production in effector CD8+ T-cells after PMA/I stimulation. (B) Percentages of cytokine production 
in effector CD8+ T-cells upon SEB stimulation. 
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Figure 6 Percentages of cytokine production in EM CD8+ T-cells. (A) Percentages of cytokine 
production in EM CD8+ T-cells upon PMA/I stimulation. (B) Percentages of cytokine production in 
EM CD8+ T-cells upon SEB stimulation. 
 
 
1b. Absolute number of cytokine producing CD4+  and CD8+ T cell subsets: 
 
 The analysis of the absolute cell count is an accurate way of identifying the 
pattern of cytokine producing based on the complete blood count (CBC) from each 
specific animal. CBC is a hematology laboratory test that provides important basic 
information about the host immune system. T lymphocyte count is an important 
parameter in HIV/AIDS clinical tests and related experimental researches. In this 
analysis, I analyzed the absolute numbers of cytokine-producing CD4+ or CD8+ T cells 
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based on the complete blood count (CBC) and the percentages of each cytokine 
producing cells from each animal. The result of the absolute cell count is presented as the 
number of cells per microliter. The data with significant differences for the absolute 
number of the cytokine producing cells will not correspond entirely with the data for the 
percentages of cytokine production since CBC data for the lymphocyte count of each 
animal was taken into account for the calculations of the absolute cell count and the CBC 
values will vary from animal to animal. The data for the absolute cell count should 
provide information on the quantity of cells that are able to secrete certain cytokines. The 
table below (Table 1) shows an example of the lymphocyte count per mm3 from the CBC 
for each animal used in this experiment. The number of T cells, CD4+ and CD8+ were 
calculated by taken together the CBC data and the analysis of cells via FlowJo software. 
 
Table 1: CBC data for the lymphocyte count of 10 young and 10 old RM that were used in the 
experiment. The number of lymphocytes represent cells per mm3. The total number of T cells along 
with the count of CD4+ and CD8+ cells were calculated based on the analysis from FlowJo software. 
 
Data from CBC
# of Lymphocytes # of T cells # of CD4 # of CD8
Old #1 1870 1099 644 749
Old #2 2500 1741 1216 1048
Old #3 2360 1333 884 874
Old #4 2090 1218 830 760
Old #5 3700 2654 1480 1821
Old #6 3010 2043 1153 1268
Old #7 1460 897 627 575
Old #8 1380 791 476 490
Old #9 2310 1364 800 906
Old #10 3360 1950 1115 1160
Young #1 2250 1609 986 887
Young #2 2751 1720 977 1153
Young #3 4211 2374 1649 1517
Young #4 5424 3522 2196 2042
Young #5 2544 1628 1121 1141
Young #6 5151 2933 1962 1858
Young #7 4910 3517 2101 2449
Young #8 3411 2449 1583 1439
Young #9 7112 4245 2915 2938
Young #10 3498 2422 1344 1405
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 The first significant difference that was observed in the data for the absolute cell 
count was from the group treated with PMA/I stimulation which showed a significantly 
higher count for IFN-γ and TNF-α production in CD4+  effector cells from the younger 
RM with *P-value < 0.05 (Figure 6A) while no significant differences were seen in the 
same subset with SEB treatment (Figure 6B and 6D). In the multifunctional population of 
CD4+ effector cells, cytokine production with a the absolute cell count for IFN-γ+ IL-2+ 
TNF-α+ producing cells was significantly higher in the younger population (Figure 6C). 
As for the subset of CD4+ central memory (CM) cells, younger population showed 
significantly higher absolute count of each cytokines producing cells (IFN-γ , IL-2, and 
TNF-α) (Figure 7A) as well as IFN-γ+ IL-2+ producing multifunctional CD4+  CM cells 
upon PMA/I stimulation (Figure 7C). Upon SEB treatment, the absolute number of IL-2 
producing CD4+  CM cells were siginificantly higher in the young population with **p-
value < 0.01 (Figure 7B) but no significant differences were seen in the CD4+  CM 
multifunctional cell count (Figure 7D). The next subset with significant differences 
between the two age groups is the cell count for CD4+ effector memory (EM) subset with 
significantly higher cell count for each IL-2 and TNF-α producing cells in the younger 
population upon both PMA/I (Figure 8A) and SEB stimulation (Figure 8B). Furthermore, 
the multifunctional CD4+ EM cells producing all three cytokines IFN-γ+ IL-2+ TNF-α+ 
showed a significant difference between the two age groups in upon both PMA/I (Figure 
8C) and SEB treatment (Figure 8D). However, another significant difference was also 
seen in the multifunctional CD4+ EM cells that secrete IL-2+ TNF-α+ upon SEB 
stimulation (Figure 8D). For the subset of CD4+ naïve cells, the only observable 
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significant difference was in the cell count for IFN-γ secreting cells upon PMA/I 
stimulation (Figure 9A) and non upon SEB treatment (Figure 9B).  
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Figure 7: Absolute number of cytokine producing CD4+ effector cells after (A) PMA/I stimulation 
and (B) SEB stimulation. (C) Absolute number of multifunctional CD4+ effector T cells upon PMA/I 
stimulation and (D) SEB stimulation. 
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Abs # CD4 IFNγ Abs # CD4 IL-2 Abs # CD4 TNFα 
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Figure 8: Absolute number of cytokine producing Central Memory (CM) CD4+ T-cells and 
multifunctional CM CD4+  T-cells. (A) Absolute number of cytokine producing CM CD4+ T-cell upon 
PMA/I stimulation and (B) SEB stimulation. (C) Absolute number of multifunctional CM CD4+ T 
cells upon PMA/I stimulation and (D) SEB stimulation. 
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Figure 9: Absolute number of cytokine producing EM CD4+  T-cells and multifunctional EM CD4+ 
T-cells. (A) Absolute number of cytokine producing EM CD4+ T-cells upon PMA/I stimulation and 
(B) SEB stimulation. (C) Absolute number of multifunctional EM CD4+ T-cells upon PMA/I 
stimulation and (D) SEB stimulation  
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Figure 10: Absolute number of CD4+ naive T cells after (A) PMA/I stimulation and (B) SEB 
stimulation 
 
 In CD8+  T-cell subset, the significant differeces were only obsereved in the 
subsets of CM, EM and naive CD8+  T cells. The significant difference seen in the subset 
of CD8+ CM cells falls in the absolute cell count of TNF-α producing cells upon PMA/I 
stimulation (Figure 10A) and again no differences were seen upon SEB stimulation 
(Figure 10B). For CD8+ EM cells, younger population had a significantly higher absolute 
cell count for IL-2 producing cell in both PMA/I treated group (Figure 11A) as well as 
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SEB treated group (Figure 11B). Moreover, samples treated with PMA/I also showed a 
significant difference in the absolute cell count of TNF-α producing CD8+  EM cells 
(Figure 11A). As for CD8+  naïve cells, younger population had a significantly higher 
absolute cell count for TNF-α producing cell, again in both PMA/I (Figure 12A) and SEB 
stimulation (Figure 12B).  
	     	  
   
Figure 11: Absolute number of cytokine producing CM CD8+ T-cells. (A) Absolute number of 
cytokine producing CM CD8+  T-cells upon PMA/I stimulation and (B) SEB stimulation  
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Figure 12: Absolute number of cytokine producing EM CD8+  T-cells after (A) PMA/I stimulation 
and (B) SEB stimulation 	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Figure 13: Absolute number of cytokine producing CD8+  naive T-cells after (A) PMA/I stimulation 
and (B) SEB stimulation  
 
 
1c. Mean Fluoresence Inentsity (MFI) of cytokine producing CD4+  and CD8+  T cell 
subsets 	  
 Mean Fluoresence Inentsity (MFI) is the fluorescence intensity or the brightness 
of each event in average that represents the expression quantity of the chosen parameter 
on each event. In this paper, MFI is used to quantify the measurement of the cytokine 
production per cell. All of the MFI values were retrieved from FlowJo (Treestar, Inc.).  
MFI were evaluated for both single-cytokine secreting cells and for multifunctional cells. 
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Each cytokine secreted in multifunctional cells or multiple cytokine secreting cells were 
assessed individually. For example, the MFI values for multifunctional cells secreting all 
of the three cytokines (IFN-γ+ IL-2+ TNF-α+) were assessed for IFN-γ , IL-2 and TNF-α 
individually and the values of each cytokine produced in the multifunctional cells were 
compared between the two age groups.  The significant differences of MFI were detected 
only in subset of central memory of CD4+  and CD8+  multifunctional T-cells. Figure 13 
compares the MFI of multifunctional CD4+ CM cells upon the treatment of PMA/I 
(Figure 13A) versus SEB (Figure 13B). However a significant difference was found in 
the values for IL-2 in multifunctional cells secreting IFN-γ+ IL-2+ TNF-α+ and that were 
treated with SEB (Figure 13B). Similarly for CD8+ CM cells (Figure 14), the significant 
difference was observed in the SEB treated group but with this subset, the significant 
difference was found in the IFN-γ of multifunctional cells secreting IFN-γ+ TNF-α+ 
(Figure 14B). Again no significant differences were found in PMA/I stimulated group of 
CD8+  CM cells (Figure 14A).   
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Figure 14: MFI of cytokine producing multifunctional CD4+  CM T-cells upon (A) PMA/I 
stimulation and (B) SEB stimulation. 
 
	  
	  
Figure 15: MFI of cytokine producing multifunctional CD8+  CM T-cells upon (A) PMA/I 
stimulation and (B) SEB stimulation. 	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2. Younger rhesus macaques showed greater T cell responses after antigen-
specific stimulation (CMV, SIVenv peptide, SIVgag peptide) 
 
2a. Percentage of cytokine production from CD4+  and CD8+  T cell subsets 
 
 Apart from observing the immune responses upon generalized T-cell activation, 
an antigen-specific response was also tested. This observation of antigen specific immune 
responses is a step closer to those immune responses seen upon the actual infection. 
Immunological mechanisms involved in protective immunity against lentiviral infections 
are crucial to the development of an effective vaccine. In the aspect of HIV infection, 
antigen-specific T cells responses also play a key role during acute and chronic HIV 
infection. Since test subjects were not infected with SIV, the secretion of specific 
immune response is not highly anticipated. However, the immune response activated by 
SIV peptides in these pre-infected subjects are expected to be produced by cross 
reactivity between the immune cells and SIV peptides. This study will allow the 
exploration of the ability for pre-infected RM to react to SIV peptides which might be 
correlated to the immune activation post infection. Antigen-specific responses in CD4+ 
and CD8+  T cells were then observed in this experiment. To investigate this, PBMC of 
20 uninfected RM (10 young and 10 old) were stimulated with SIVgag peptide and 
SIVenv peptide as well as CMV to test for the potential of the cells to response to 
different antigen specific stimulants. HIV/AIDS-relevant parameters will be assessed and 
compared between the two age groups. RM PBMC were treated with 2.5ug/mL of 
SIVgag peptive, SIVenv peptide and CMV peptide. CMV peptide was used as a control 
to assess the specificity of the SIV-related peptide upon stimulation. I then assessed the 
percentages of the cytokine producing cells, absolute numbers of cytokine producing 
cells and the mean fluorescence intensity (MFI) of each cytokine. Both single-cytokine 
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secreting cells and multifunctional cells were assessed. Gating procedure and the 
classification of the T-cell subsets were also tested as mentioned in the previous 
experiment.  
 Figure 15 shows the percentages of cytokine production from CD4+  effector 
memory (EM) cells with significant differences between the two age groups on the 
production of IL-2 upon both SIVgag (Figure 15A) and SIVenv (figure 15B) treatment. 
However, a significant difference of IFN-γ producing cells was observed in CMV 
treatment group. As for the percentages of multifunctional CD4+  EM cells (Figures 15D-
15F), young population had significantly higher percentage of IFN-γ+ IL-2+ TNF-α+ 
producing cells upon stimulation with SIVgag peptide (Figure 15D) and higher 
percentage of IL-2+ TNF-α+ producing cells upon stimulation with CMV peptide (Figure 
15F). But no significant differences were seen upon SIVenv peptide stimulation (Figure 
15E). The other subset of CD4+  upon antigen-specific stimulation that showed a 
significant difference was the percentage of IFN-γ -producing naïve CD4+  T-cells upon 
CMV treatment (Figure 16C) and interestingly, no significant differences were observed 
in neither SIVgag nor SIVenv peptide stimulated group (Figure 16A-16B).  
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Figure 16: Percentages of cytokine production in effector memory (EM) CD4+  T-cells and 
multifunctional EM CD4+  T-cells. (A) Percentage of cytokine secretion from CM CD4+  T-cells after 
SIVgag peptide stimulation.  (B) Percentage of cytokine secretion from EM CD4+  T-cells after 
SIVenv peptide stimulation. (C) Percentage of cytokine secretion from EM CD4+  T-cells after CMV 
peptide stimulation (D) Percentage of multifunctional EM CD4+  T-cells after SIVgag peptide 
stimulation, (E) SIVenv peptide stimulation and (F) CMV peptide stimulation.  
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Figure 17: Percentages of cytokine production in CD4+ naïve T-cells and multifunctional naive CD4+  
T-cells. (A) Percentage of cytokine secretion from CD4+ naïve T-cells upon SIVgag peptide 
stimulation, (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
 
 
As for the subset of CD8+  T-cells, more significant differences were obsereved in 
the subsets of CD8+  effector cells (Figure 17), CD8+  CM cells (Figure 18) and CD8+  
EM cells (Figure 19). In the subset of CD8+  effector cells, a significant difference was 
seen in percentage of IFN-γ -producing cells upon SIVgag peptide stimulation (Figure 
17A) and another significant difference was observed in the percentage of IL-2-
producing CD8+  effector cells upon CMV stimulation (Figure 17C). For the central 
memory compartment of CD8+ , the young population only had a significantly higher 
percentage of IL-2 secretion upon the treatment with SIVenv peptide (Figure 18B), while 
no significant differences were found in the groups stimulated with SIVgag peptide 
(Figure 18A) nor CMV peptide (Figure 18C). The last group is CD8+  EM cells, with a 
critically higher percentages of IL-2 secreting CD8+  EM cells in the young upon SIVgag 
peptide stimulation (***p-value <0.000) and as well as upon SIVenv peptide stimulation 
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(* p-value <0.05) (Figure 19A-19B). Yet, no significant values were found upon CMV 
stimulated group (Figure 19C).  
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Figure 18: Percentages of cytokine production in CD8+  effector T-cells (A) Percentage of cytokine 
secretion from CD8+  effector T-cells upon SIVgag peptide stimulation, (B) SIVenv peptide 
stimulation and (C) CMV peptide stimulation. 
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Figure 19: Percentages of cytokine production in CM CD8+  T-cells and multifunctional CM CD8+  
T-cells. (A) Percentage of cytokine secretion from CM CD8+  T-cells upon SIVgag peptide 
stimulation, (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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% of CD8: IFNγ % of CD8: IL-2 % of CD8:TNFα  
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Figure 20: Percentages of cytokine production in EM CD8+  T-cells and multifunctional EM CD8+  T-
cells. (A) Percentage of cytokine secretion from EM CD8+  T-cells upon SIVgag peptide stimulation, 
(B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
 
 
2b. Absolute number of cytokine producing CD4+  and CD8+  T cell subsets 
  
 The protocol for calculaing the absolute number of cytokine producing T cells 
upon antigen specific stimulation is the same as the one mentioned in the previous section 
of mass stimulation. Starting with the significant differences in the subset of CD4+  CM 
cells. The significant differences between the two age groups in the absolute count in IL-
2 producing cells were seen in all of the treatment groups, SIVgag, SIVenv and CMV 
peptide stimulations (Figure 20A-C). However, an additional significant difference was 
seen upon CMV peptide stimulation in the absolute count of TNFα-producing cells 
(Figure 20C). For CD4+  EM T cells subset, significant differences were observed in all 
of the treatment groups. Upon SIVgag and SIVenv peptide stimulation, younger 
population showed a significantly higher count in IL-2 secreting cells (Figure 21A-B). 
On the other hand, significant differences were seen in single cytokine secreting CD4+  
EM cells that were secreting IFN-γ , IL-2, and TNF-α in the subset treated with CMV 
% of CD8: IFNγ % of CD8: IL-2 % of CD8:TNFα  
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peptide (Figure 21C). The last group of CD4+ that showed a significant difference is the 
CD4+  naïve T cells with a significant difference in the count of TNF-α secreting cells 
upon SIVgag peptide stimulation (Figure 22A). In contrast, no other significant 
differences were seen upon other peptide treatments (Figure 22B-C). Interestingly, no 
significant differences were observed in the absolute count of multifunction cells of CD4+  
and CD8+  (not shown).  
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Figure 21: Absolute number of cytokine producting CM CD4+  T cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 22: Absolute number of cytokine producting EM CD4+ T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 23: Absolute number of cytokine producting CD4+ naïve T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
 
 CD8+  T cells is another set of T cells that were analyzed and the sifinficant 
differnces were seen in the CD8+  effector T cells, CM and EM subsets. In the subset of 
CD8+  effector T cells, the siginificant differences between the age groups were seen in 
the count of IL-2 secreting cells that were treated with SIVgag peptide and CMV peptide 
(Figure 23A and 23C) but no significant differnces were soon upon SIVenv peptide 
treatments (Figure 23B). As for CD8+  CM subset, more significant difference were seen 
across different cytokine secretion. Upon SIVgag peptide stimulation, younger 
population had a significantly higher count in IFN-γ secreting cells as well as IL-2 
secreting cells (Figure 24A) and for the group treated with SIVenv peptide, younger 
population had a significantly higher count in IL-2 secreting cells and TNF-α secreting 
cells (Figure 24B). On the other hand, CMV stimulated group showed a significant 
difference in  count in IL-2 secreting cells with ***P-value < 0.000. Lastly, CD8+  EM 
cells subset upon all three stimulation showed significant differences with younger 
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population having a high absolute cell count in IL-2 secreting cells (Figure25A-C). 
Again, no significant differences were detected in the absolute count of any 
multifunctional cells (not shown).  
 
	     	  
 
Abs # CD8 IFNγ Abs # CD8 IL-2 Abs # CD8 TNFα 
Old population 1 48 4 
Young population 5 113 10 
0 
50 
100 
150 
200 
250 
# 
of
 c
el
ls
 / 
uL
 
Gag peptide Stimulation: Absolute number of cytokine producing 
CD8 effector cells 
A. 
!!*!
Abs # CD8 IFNγ Abs # CD8 IL-2 Abs # CD8 TNFα 
Old population 0 75 6 
Young population 12 170 16 
0 
50 
100 
150 
200 
250 
# 
of
 c
el
ls
 / 
uL
 
Env peptide Stimulation: Absolute number of cytokine producing 
CD8 effector cells 
B. 
	   61	  
	  
	  
Figure 24: Absolute number of cytokine producting effector CD8+  T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 25: Absolute number of cytokine producting CM CD8+  T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 26: Absolute number of cytokine producting EM CD8+ T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
 
2c. Mean Fluoresence Intensity (MFI) of of cytokine producing CD4+  and CD8+  T 
cells subsets 
 
 The last analysis for the antigen specific is the MFI analysis. The first observable 
significant difference appeared in the floresence of  TNF-α in multifunctinal effector 
CD4+  T cells screting IFN-γ+ IL-2+ TNF-α+ upon SIVgag peptide stimulation (Figure 
26A) and SIVenv peptide stimulation (Figure 26B). Furthermore, in the group treated 
with SIVgag peptide, the younger population also showed a higher MFI value in the 
florescence of both IFN-γ and IL-2 in the multifunctinal effector CD4+  T cells screting 
IFN-γ+ IL-2+ (Figure 26A). However, no significant differences were seen with CMV 
stimulation (Figure 26C). Figure 27 shows the MFI data for the multifunctional CD4+  
CM cells with significant differences between the two age groups in the flouresence 
intensity of IFN-γ and IL-2 from the multifunctinal CD4+ CM T cells screting IFN-γ+ IL-
2+ upon SIVgag peptide stimulation (Figure 27A) as well as CMV peptide stimulation 
(Figure 27C). Another set of significant difference was observed upon SIVenv peptide 
stimulation in the fluorescence intensity of IFN-γ from the multifunctinal CD4+ CM T 
cells screting all three cytokines IFN-γ, IL-2 and TNF-α (Figure 27B). Interestingly, in 
the subset of CD4+ EM cells, the only significant differences were seen in the group 
stimulated with SIVgag peptide which falls showed a significantly higher MFI value in 
the younger population in the fluorescence intensity of IFN-γ and IL-2 from the 
multifunctional CD4+ EM T cells screting IFN-γ and IL-2 (Figure 28A). No other 
significant differences were seen in SIVenv peptide nor CMV peptide treated groups 
(Figure 28B-C). However, in the subset of naïve CD4+  Tcells, both single cytokine 
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secreting cells and multifunctional cells had significant differences between the two 
groups with a higher MFI in the young population in both SIVgag and SIVenv peptide 
stimulation. Upon SIVgag stimulation, all of the significant differences of MFI were 
observed in each cytokine (IFN-γ , IL-2 and TNFα) in the single cytokine producing 
CD4+  naïve cells (Figure 29A) but for SIVenv peptide stimulated group, the significant 
differences was seen only in IL-2 secreting cells (Figure 29B). As for multifunctional 
CD4+ naïve cells, again SIVgag treatment group showed a significantly higher MFI value 
in the younger population in the fluorescence intensity of IFN-γ  , IL-2 and TNFα from 
the multifunctional CD4+  naive T cells screting all three cytokines (IFN-γ , IL-2 and 
TNFα) (Figure 29D). While SIVenv treated group showed significant difference only in 
the fluorescence intensity of TNFα in the same type of multifunctional cell which is the 
multifunctional CD4+ naive T cells screting all three cytokines (IFN-γ , IL-2 and TNFα) 
(Figure 29E). No significant difference was observed in CMV stimulation (Figure 29C, 
29F). 
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Figure 27: MFI of cytokine producing multifunctional CD4+ effector cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 28: MFI of cytokine producing multifunctional CM CD4+  T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 29: MFI of cytokine producing multifunctional EM CD4+  T-cells upon (A) SIVgag peptide 
stimulation (B) SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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MFI: IFNγ MFI: IL-2   MFI: TNFα  
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Figure 30: MFI of cytokine producing CD4+ naive T-cells. (A) MFI of cytokine producing CD4+  
naive T-cells upon SIVgag peptide stimulation, SIVenv peptide stimulation and (C) CMV peptide 
stimulation. (D) MFI of of cytokine producing multifunctional CD8+  naive T-cells upon (D) SIVgag 
peptide stimulation, (E) SIVenv peptide stimulation and (F) CMV peptide stimulation.   
 
 The subset of CD8+  T cells showed less significant values  of MFI data when 
compared to CD4+  T cells under the same antigen specific stimulants with no significant 
differences seen in under the stimulation of CMV peptide (Figure 30C, 31C). The 
significant differences of MFI between the two age groups is seen in the subset of CD8+  
effector cells from both SIVgag and SIVenv peptides stimulation. Upon SIVgag peptide 
stimulation, young population had a significantly higher MFI values of IL-2 and TNFα 
from single cytokine secreting cells (Figure 30A) while the same CD8+  subset under 
SIVenv peptide stimulation had the significant difference only in the MFI value of IL-2 
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from single cytokine secreting cells (Figure 30B). The last CD8+  subset with significant 
difference in the MFI data is the CD8+  EM cells, with a significant difference in the MFI 
of IL-2 in from single cytokine secreting cells upon SIVgag peptide stimulation (Figure 
31A) and significant differences in the MFI of both IL-2 and TNFα from single cytokine 
secreting cells under SIVenv peptide stimulation (Figure31B).  
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Figure 31: MFI of cytokine producing CD8+  effector cells upon (A) SIVgag peptide stimulation, 
SIVenv peptide stimulation and (C) CMV peptide stimulation. 
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Figure 32: MFI of cytokine producing EM CD8+  T-cells upon (A) SIVgag peptide stimulation, 
SIVenv peptide stimulation and (C) CMV peptide stimulation. 
3. Proliferative capacity of T cells upon stimulation with Anti-CD3, 
SIVSIVgag peptide and CMV peptide using Ki-67 antibody staining. 
 
 The proliferative capacity of T-cells was determined in this part of the experiment 
by observing the expression of Ki-67 in T cell subsets of CD4+  and CD8+. Ki-67, a 
nuclear antigen expressed in the G1, G2, S, and M phases but not the G0 phase of the cell 
cycle, which makes it a useful index of cell prolifreation (32). Intracellular staining for 
the Ki-67 antigen, which enabled accurate measurement of proliferating cells in response 
different stimulants. In this experiment, I treated the samples with 3 different conditions 
with 1 control group. Stimulants used in this study include, Anti-CD3, SIVgag and CMV 
peptides. Two costimulatory signals were provided by anti-CD28 and anti-CD4+ 9d 
antibodies. All of these stimulants have the same mode of activation, which is the 
formation of complex with the TCR. The use of antibodies against the CD3 complex is a 
specific stimulus for activating T cells and it is commonly used as a T cell activator. 
Anti-CD3 antibodies have the ability to provide an initial activation signal but require the 
addition of costimulatory antibodies to provide the stimulus for robust proliferation. An 
important role of costimulation is to prolong the survival of activated T cells (The role of 
the CD28 receptor during T cell responses to antigen). SIVgag was chosen as one of the 
stimulants because Gag-specific immune response is one of the relevant immunological 
factors that is associated with HIV/SIV viral control. 
PBMC from a total of 6 young and 6 old uninfected RM were used in the 
experiment. The surface markers, CD3, CD4+  and CD8+  were used to classify CD4+  
and CD8+  into 4 subsets including CD4+ , CD8+ , CD4+ CD8+  and CD4- CD8- T cells.   
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3a. Percentages of Ki-67 expression in CD4+ and CD8+ T cells 
 
The first set of data demonstrated the percentages of Ki-67 expression in different 
subsets of CD4+ and CD8+  T cells. Figure 32 shows graphs comparing the expression of 
Ki-67 of the two age groups in different subsets of T cells upon three different stimulants. 
Figure 32A shows an interesting result of a significantly higher percentage of Ki-67 
expression in CD4+ T cells when compared to the young. However, upon SIVgag peptide 
stimulation (Figure 32B), an opposite effect was observed. Young population showed a 
significantly higher percentage of Ki-67 expression in CD4+  T cells. No significant 
differences of Ki-67 expression were observed in samples treated with CMV peptide. 
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Figure 33: Percentages of Ki-67 expression in CD4+ and CD8+  T-cell subsets upon (A) Anti-CD3 
stimulation, (B) SIVSIVgag peptide stimulation and (C) CMV peptide stimulation.  
   
3b. Absolute number of Ki-67 expressing CD4+ and CD8+  T cells 
 
The principal of a calculating the absolute numbers of Ki-67 expressing T cells 
follows the same protocol as mentioned in the first and second specific aims. Figures 33 
A-C provided the data for the absolute number of cells that were expressing Ki-67. The 
overall picture shows a higher absolute cell count in the young population except in the 
absolute cell count of Ki-67 expression in CD4+  T cells after Anti-CD3 stimulation. 
However, no significant differences were found in any of the treatment group for this part 
of the analysis.  
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Figure 34: Absolute number of Ki-67 expression in CD4+  and CD8+  cells upon (A) Anti-CD3 
stimulation, (B) SIVSIVgag peptide stimulation and (C) CMV peptide stimulation.   
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Table 2: Summary table of the percentages of cytokine production upon mass stimulations and 
antigen specific stimulations.  Y=Young population; O=Old population. Value of significance: P < 
0.05 *, P < 0.01 **, P < 0.001 ***. 
 
 
Percentages of cytokine production
Triple cytokine production
Stimulants T cell subsets  IFNγ  IL-2 TNFα  IFNγ IL-2  IFNγ TNFα  IL-2 TNFα  IFNγ IL-2 TNFα 
PMA&I CD4 Effector cells - - - - - Y > O (*) -
CD4 CM cells Y > O(*) Y > O(*) Y > O(*) - Y > O(*) - -
CD4 EM cells - Y > O(*) - - - - -
CD4 Naïve cells - - - - - - -
CD8 Effector cells - - - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - Y > O(*) - - - - -
CD8 Naïve cells - - - - - - -
SEB CD4 Effector cells - - - - - - -
CD4 CM cells - - - - - - -
CD4 EM cells - Y > O (***) - - - Y > O (***) -
CD4 Naïve cells - - - - - - -
CD8 Effector cells - Y > O (**) - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - Y > O (*) - - - - -
CD8 Naïve cells - - - - - - -
SIVgag CD4 Effector cells - - - - - - -
CD4 CM cells - - - - - - -
CD4 EM cells - Y > O (*) - - - - Y > O (*)
CD4 Naïve cells - - - - - - -
CD8 Effector cells Y > O (*) - - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - Y > O (***) - - - - -
CD8 Naïve cells - - - - - - -
SIVenv CD4 Effector cells - - - - - - -
CD4 CM cells - - - - - - -
CD4 EM cells - Y > O (**) - - - - -
CD4 Naïve cells - - - - - - -
CD8 Effector cells - - - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - Y > O (*) - - - - -
CD8 Naïve cells - - - - - - -
CMV CD4 Effector cells - - - - - - -
CD4 CM cells - - - - - - -
CD4 EM cells Y > O (*) - - - - Y > O (*) -
CD4 Naïve cells Y > O (*) - - - - - -
CD8 Effector cells - Y > O (**) - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - - - - - - -
CD8 Naïve cells - - - - - - -
Single cytokine production Double cytokine production
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Table 3: Summary table of the absolute count of cytokine prodcuing cells upon mass stimulations 
and antigen specific stimulations.   
    
Absolute count of cytokine production
Triple cytokine production
Stimulants T cell subsets  IFNγ  IL-2 TNFα  IFNγ IL-2  IFNγ TNFα  IL-2 TNFα  IFNγ IL-2 TNFα 
PMA&I CD4 Effector cells Y > O (***) - Y > O (*) - - - Y > O (*)
CD4 CM cells Y > O (**) Y > O (*) Y > O (**) Y > O (*) - - -
CD4 EM cells - Y > O (**) Y > O (**) - - - Y > O (*)
CD4 Naïve cells Y > O (*) - - - - - -
CD8 Effector cells - - - - - - -
CD8 CM cells - - Y > O (*) - - - -
CD8 EM cells - Y > O (*) Y > O (*) - - - -
CD8 Naïve cells - - Y > O (**) - - - -
SEB CD4 Effector cells - - - - - - -
CD4 CM cells - Y > O (**) - - - - -
CD4 EM cells - Y > O (***) Y > O (*) - - Y > O (**) Y > O (**)
CD4 Naïve cells - - - - - - -
CD8 Effector cells - - - - - - -
CD8 CM cells - - - - - - -
CD8 EM cells - Y > O (***) - - - - -
CD8 Naïve cells - - Y > O (*) - - - -
SIVgag CD4 Effector cells - - - - - - -
CD4 CM cells - Y > O (*) - - - - -
CD4 EM cells - Y > O (**) - - - - -
CD4 Naïve cells - - Y > O (*) - - - -
CD8 Effector cells - Y > O (*) - - - - -
CD8 CM cells Y > O (*) Y > O (*) - - - - -
CD8 EM cells - Y > O (**) - - - - -
CD8 Naïve cells - - - - - - -
SIVenv CD4 Effector cells - - - - - - -
CD4 CM cells - Y > O (**) - - - - -
CD4 EM cells - Y > O (*) - - - - -
CD4 Naïve cells - - - - - - -
CD8 Effector cells - - - - - - -
CD8 CM cells - Y > O (**) Y > O (**) - - - -
CD8 EM cells - Y > O (**) - - - - -
CD8 Naïve cells - - - - - - -
CMV CD4 Effector cells - - - - - - -
CD4 CM cells - Y > O (**) Y > O (*) - - - -
CD4 EM cells Y > O (*) Y > O (**) Y > O (*) - - - -
CD4 Naïve cells - - - - - - -
CD8 Effector cells - Y > O (**) - - - - -
CD8 CM cells - Y > O (***) - - - - -
CD8 EM cells - Y > O (*) - - - - -
CD8 Naïve cells - - - - - - -
Single cytokine production Double cytokine production
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Table 4: Summary table of MFI values of the cytokines upon mass stimulations and antigen specific 
stimulations.   
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Table 5: Summary table of percentages, absolute cell count and MFI values of Ki-67 expression upon 
differnt stimulants. 
 
4. Multivariate Analysis: Principal component analysis	    
 
 Since this study tested multiple variables, multivariable analysis was applied. 
Principal component analysis was used as a method of analysis to reduce or condense the 
variables in the data set into “Principal components” (PC). PC with the largest 
contribution to the variance of the data will define the important parameters that 
contribute most to the data set, which can be used to distinguish the immunological 
parameters that contribute most to the data set and help to identify the parameters that 
best discriminate between the old and young Rhesus macaques. Tables below show three-
dimensional graphs of the three main analyses of CD4+  and CD8+  T-cells, which are the 
frequencies, absolute cell count and mean fluorescence intensity of the cytokine 
productions. Correlation coefficients which define each principal component are plotted 
in the three dimensional graphs. A high correlation between PC and a variable indicates 
Prolifeative capacity
Stimulants T cell subsets % Ki-67 Abs cell count: KI-67
Anti-CD3 CD4+ Y < O (*) -
CD8+ - -
CD4+CD8+ - -
CD4-CD8- - -
SIVgag CD4+ Y > O (*) -
CD8+ - -
CD4+CD8+ - -
CD4-CD8- - -
CMV CD4+ - -
CD8+ - -
CD4+CD8+ - -
CD4-CD8- - -
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that the variable is strongly associated with maximum variation in the data set. However 
the significance of the separation between the two age groups with multiple variables 
cannot be calculated statistically so the graphs below only show visual displays of the 
data and the separation of the two sample groups can be visually determined.  
 Figure 34 demonstrate the frequencies of cytokine production in both total 
cytokine production multiple cytokine production (Boolean) or CD4+ and CD8+  T cells. 
The best separation between the two groups is seen in Figure 34C which is the multivariate	  data	  analysis	  of	  the	  frequency	  of	  cytokine	  production	  in	  CD8+ multiple-­‐cytokine	  production	  and	  in	  figure	  34E	  which	  shows	  the	  multivariate	  data	  analysis	  of	  the	  frequency	  of	  total	  cytokine	  production	  of	  T	  cells	  including	  both	  CD4+ 	  and	  CD8+ . 
 
Figure 35 Multivariate data analysis of the frequency of cytokine production in (A) CD4+  multiple-
cytokine production, (B) CD4+  total cytokine production, (C) CD8+  multiple-cytokine production, 
(D) CD8+  total cytokine production and (E) total cytokine production of T cells 	  
A. B. C. 
D. E. 
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However, the clearer separation between the two groups can be seen across the T cell 
subsets in the multivariate data analysis of the absolute cell count (Figure 35). The best 
separation of the two groups appear in Figure 35A which demonstrate the analysis of the 
absolute count of cytokine producing cells in CD4+  multiple-cytokine production as well 
as figure 35B, which shows the data analysis of the absolute count of total cytokine 
production in CD4+  cells. Figure 35E, which demonstrate the absolute count of the total 
cytokine production of T cells also shows a clear clustering of the two groups and this 
provide a clear visualization of the separation.  
	  
Figure 36 Multivariate data analysis of the absolute count of cytokine producing cells in (A) CD4+  
multiple-cytokine production, (B) CD4+  total cytokine production, (C) CD8+  multiple-cytokine 
production, (D) CD8+  total cytokine production and (E) total cytokine production of T cells 
 The differentiation between the two groups in the context of MFI is not very clear 
in the graphs shown in Figure 36.  However, Figures 36B and 36C seem to show some 
separation between the two age groups. The purple dots appear towards the front of the 
A. B. C. 
D. E. 
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3D graph while the green dots tend to stay at the back. There two figures display a visual 
separation of the MFI values of CD4+  total cytokine production (Figure 36B) and CD8+  
multiple-cytokine production (Figure 36C). 
	  
Figure 37 Multivariate data analysis of the Mean Fluorescence Intensity (MFI) of cytokine 
production in (A) CD4+ multiple-cytokine production, (B) CD4+  total cytokine production, (C) CD8+  
multiple-cytokine production, (D) CD8+  total cytokine production and (E) total cytokine production 
of T cells 
Discussion 
  
In this study, T cell responses were compared between rhesus macaques of young 
adult age and those of advanced age. My interest in the study stems from the fact that 
acquiring HIV or SIV infection at advanced age is associated with accelerated 
progression to AIDS. Based on this phenomenon, I postulated that some immune 
responses that are crucial to limiting viral replication and pathogenesis during acute 
infection are lacking in older animals. Therefore, I selected certain T cell responses 
whose associations with better outcomes in HIV/SIV disease have been previously 
A. B. C. 
E. D. 
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demonstrated to test my hypothesis. This work has been done using blood samples from 
uninfected animals. Pre-infection studies provide an opportunity to define intrinsic 
differences that might have resulted in the divergent outcome in an unaltered immune 
system. The question targeted in this study was whether or not the younger population 
will be able to illustrate more potent immune responses associated with better outcomes 
of the disease when compared to the old population upon treatment with different 
stimulants and which immunological parameters are most discriminatory between the two 
groups. To answer this question, PBMC of uninfected old and young RM were treated 
with different stimulants including mass stimulants and antigen specific stimulants, to test 
for the potential of the cells and to compare between the two age groups with different 
disease progression patterns. Moreover, this study also looked for the immunological 
parameters that distinguish the two age groups. The potential of T cells were determined 
by the secretion of three cytokines IL-2, IFN-γ and TNF-α in terms of frequency, 
absolute numbers, and mean fluorescence intensity (MFI).   
By stimulating the cells bypassing the T cell receptors using PMA/I, a variety of 
cells were stimulated, which enables the observation and comparison of the overall 
potential of cells to mount protective immune response in the two age groups. The result 
of this study shows a higher potential of T cells in most subsets from the young 
population through this type of stimulation. Next, the stimulation with SEB was done to 
determine and compare the ability for cells to mount protective immune responses 
through the interaction with the superantigen and T cell receptors. As expected, cells 
from the young RM showed stronger potential to mount protective immune response 
upon SEB stimulation, especially in the percentage of IL-2 positive cells. The last 
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stimulation concentrated specifically on the responses towards SIV peptide (pool) 
stimulations, which brings the focus of the immune response to a specific group. Since 
the tested subjects are not infected with the virus, I did not expect to see a high secretion 
of SIV specific immune responses but some cross reactivities between the T cell 
receptors and SIV peptides was expected. CMV stimulated group was tested along side 
with SIV peptide stimulation to identify they specificity of the immune responses towards 
SIV pooled peptides. Once again, the younger subjects showed a higher potential of T 
cell responses towards SIV peptides. SIV peptides stimulations was considered to be 
SIV-specific since the pattern of significant differences (in terms of frequencies) for each 
T cell subsets between the two age groups were similar upon the treatment with SIVgag 
and SIVenv peptides (Table 1). While the pattern of cytokine production upon CMV 
peptide did not truly correspond to the SIV peptides.  
The overall investigation of cytokine productions in this study shows that the 
protective immune responses, including the secretion of IL-2, and the abundance of 
multiple cytokine-secreting cells, were observed more from the younger RM. This 
finding agrees with the central hypothesis, which stated that critical immune responses, 
such as those associated with better outcome in primate lentiviral infections are lost in 
rhesus macaques at older age. This finding corresponds with previous studies on the 
negative impacts of aging on the magnitude of the immune response. Studies in the past 
have shown dramatic differences in the quality of the T-cell responses when comparing 
HIV-infected progressors with LTNPs. One study reported an increase in the frequencies 
of T cells expressing IL-2 only or both IL-2 and IFN-γ together as well as a higher 
frequency of IL-2+ TNF-α+ IFN-γ+ (triple cytokine production) in LTNP and HIV 
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infected patients who received HAART therapy when compared to untreated patients (35, 
36). However, most of the significant differences in my study were seen in the secretion 
of single cytokines rather than the secretion of double or triple cytokine secretions.  
According to the summary chart in Table 1, most of the significant differences in 
the percentage of cytokine production of IL-2 mostly came from the memory subsets of 
CD4+ and CD8+ T cells, which showed a higher secretion of this cytokine from the young 
population. According to past studies, IL-2 production and multi-cytokine secretion from 
the memory subsets of T cells correspond to a better prognosis of the disease progression. 
Potter et al, showed that HIV controllers or LNTP, are able to maintain potent functional 
activation in the CD4+ memory cell compartments. This group of people is able to 
preserve high IL-2 secretions in the memory compartments of T cells (66). One of the 
reasons that might explain the robust production of IL-2 from the memory compartment 
of T cells in this study is the faster activation rate of memory T cells. Memory T cells can 
perform immediate effector functions in peripheral tissues or undergo activation as well 
as clonal expansion when compared to other subsets of T cells (13). Upon stimulations or 
contact with specific antigens or peptides, the effector memory cells can achieve effector 
functions instantly, whereas central memory cells can rapidly proliferate, expand and 
acquire the effector functions. The production of IL-2 from CD4+ T cells, contribute 
largely to the clonal expansion and differentiation of CD8+ T cells. IL-2 signals are also 
able to rescue CD8+ T cells from cell death and provide a robust increase in memory 
CD8+ T-cell counts as well as encouraging the primary and secondary expansion of CD8+ 
T cells, which in turn optimizes CD8+ T-cell functions (44). Moreover, Litjens et al. 
concluded in their studies that memory CD4+ T cells that produce IL-2 is also associated 
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with the generation of IgG-secreting plasma cells (45). The robust production of IgG 
induced by IL-2 will be able to provide a stronger protective response.  
IL-2 is known for its ability to promote and regulate proliferation, differentiation, 
expansion and survival of T cells (16, 26). One study demonstrated a significant 
reduction in IL-2 production in patients with HIV infection, which results in impaired 
lymphocyte functions, and increased rate of lymphocyte apoptosis (38, 39). The weak or 
absent proliferative capacity of CD4+ T cell responses is a hallmark of progressive HIV 
infection. This is largely caused by the loss of functions, in particularly, IL-2 secretion 
(40). IL-2 can be considered as one of the most important cytokines in relation to a better 
prognosis of HIV infection. In the mid 1990s, National Institutes of Health (NIH) 
Clinical Center performed studies to evaluate the potential of IL-2 in HIV infected 
patients by administering IL-2 via continuous intravenous infusion or subcutaneous 
injection. As a result, there was a 3-4 folds increase in CD4+ T cell counts that persisted 
for up to 3 years in patients who received the treatment (41, 42, 43).  
 IFN-γ is another important cytokine commonly used to determine the potential of 
T cells. The frequency of this cytokine is also widely used as a parameter to assess 
vaccine induced responses that are able to mount cellular specific responses against 
specific infections (16).  However, in my study, few significant differences between the 
two age groups were seen in the percentage of IFN-γ production in all of the treatment 
conditions. However, if the absolute cell count is taken into consideration, the significant 
differences in IFN-γ production mainly fall under the group treated with PMA/I in central 
memory compartment and very few in the antigen specific stimulated groups (Table 2). 
This phenomenon can be explained with the fact that PMA/I are mass stimulants. They 
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are small organic compounds, which can diffuse through the cell membrane into the 
cytoplasm and bypassing TCR signaling, omitting surface receptor stimulation. Due to 
this ability of PMA/I, non-specific and mass stimulation of cells can be observed upon 
treatment. However, upon SIVgag peptide stimulation, young population had a 
significantly higher percentage of IFN-γ production in the CD8+ effector T cell subset but 
no significant differences were seen in the SIVenv peptide stimulation. When taking 
absolute numbers into account, the young population had a significantly higher cell count 
of IFN-γ production in CD8+ CM T cells instead. Studies have also shown that CD8+ T-
cell responses against the Gag protein measured by IFN-γ are associated with lower 
viremia in chronic HIV-1 infection (46,47). However, significant differences in the two 
age groups of the percentage and the absolute cell count of IFN-γ upon CMV stimulation 
falls mainly under CD4+ T-cell subset, which differs, completely from SIV specific 
stimulation. So the treatment of CMV shows a strong potential as a control group to test 
for SIV antigen activated immune responses in pre-infected RM. 
 The last cytokine production that was studied in this study is TNF-α. TNF-α is a 
pro-inflammatory cytokine that promotes death of cancer cells, signals the increase in 
inflammation and is able to enhance the proliferation of T cells (48).  In my study, no 
significant differences were seen in the percentages of TNF-α secretion in any of the 
treatment groups except for CD4+ CM cells upon PMA/I stimulation (Table 1). However, 
when looking at the absolute count of cells producing TNF-α, the significant differences 
were seen in all of the stimulants and again mostly in the PMA/I treated groups (Table 2). 
This again can be concluded by the non-specific and mass stimulation ability of PMA/I.  
Moreover, the young population displayed a significantly higher count of TNF-α 
	   91	  
	  
secreting cells in CD4+ EM and CD8+ naïve subsets after SEB treatment, in CD4+ naïve 
subset in SIVgag treatment, in CD8+ CM subset upon SIVenv treatment and lastly in 
CD4+ CM and EM subsets upon CMV treatment. The results of TNF-α secreted cell 
count did not provide any consistent pattern to conclude for any potential ability of cells 
to mount HIV/SIV protective immunity. Nonetheless, the overall observation shows that 
the data with significant difference in the production of TNF-α had a high production in 
the young population, which again agrees with past observations on the deterioration of 
the immune responses with age. This then explains the reason for the stronger ability of 
the young RM to secrete cytokines in response to stimulants. Moreover, the data in this 
study shows lower potential of cells from the old population to secrete significantly 
higher amount of TNF-α in most of the T- cell subsets. However, past studies had some 
contradicting observations with TNF-α in relation to HIV/SIV. Some studies showed that 
TNF-α is a potent inducer of viral gene expression. It is able to activate HIV-1 in 
chronically infected T cells through the activation and translocation of NF-κB, making 
the HIV-1 toll-like receptors (LTR) more accessible and resulting in viral transcription 
(49, 50, 51). This will provide the ability to promote the stimulation of HIV-1 replication 
in cultured PBMC (52). Another contradictory finding is inhibition of HIV-1 replication 
by TNF- α by down regulating the expression of CCR5 and inhibiting the entry of CCR5-
dependent viruses (53, 54). Further studies will need to be conducted to determine the 
accurate relationship between HIV/SIV proliferative capacity and TNF-α. 
 The secretions of double and triple cytokine production (multifunctional cells) 
were also determined in this study. As expected, very few significant data were observed 
in this multifunctional part of the analysis due to the fact that multifunctional T cells 
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make up a small part of the total population. According to my data, the significant 
differences in percentages of double cytokine production (Table 1), were observed upon 
PMA/I, SEB, and CMV stimulations. Significant difference of IL-2+ TNF-α+ production 
upon treatment with PMA/I, SEB and CMV were from the memory compartments of 
CD4+ T-cells. The ability for the younger RM to secrete double cytokine of IL-2+ TNF-α+ 
correspond with previous studies which provided evidences for the better prognosis of 
HIV infection in combination with the enhanced secretion of IL-2+ TNF-α+ by CD4+ 
multifunctional T cells (35). Interestingly, one significant data was observed in the 
production of triple cytokine (IFN-γ+ IL-2+ TNF-α+) from the subset of CD4+ EM T-cells 
upon SIVgag stimulation with a higher production of triple cytokine from the young 
population. Studies have shown that an increase in the multifunctional CD4+ T-cells is 
associated with an improved control of HIV upon comparison between HIV infected 
progressors and LTNPs (16). Evidence revealed that LTNPs and those who received 
treatments had higher frequencies of IFN-γ+ TNF-α+ IL-2+ or IL-2+ IFN-γ+ T cells when 
compared to the progressors (35, 55, 56). Furthermore, the presence of HIV/SIV antigen 
tends to drive CD4+ towards the production of single-cytokine which will eventually lead 
to cell death and the depletion of CD4+ T-cells but in contrast, multifunctional T cells 
have the ability to resist throughout the infection (16). According to my data of the 
percentage of multiple cytokine production, it can be concluded that young population of 
RM has more potential to mount a multiple-cytokine production in the subset of CD4+ 
EM cells upon SIVgag peptide stimulation, indicating a better chance of mounting a more 
protective immune response once in contact with the SIV. However, the absolute cell 
counts of multiple cytokine production show significant data only upon treatment with 
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mass stimulants (PMA/I and SEB) and mostly from CD4+ memory compartments. The 
reasons that the significant results from the absolute cell count analysis (Table 2) differs 
slightly from the significant data seen in the analysis of percentages of cytokine 
production is because the absolute cell count data is based on the CBC from each specific 
animal with different CBC values lymphocyte count in each animal. So the results of the 
absolute cell count measures the quantity of the cells that are capable of mounting 
protective immune responses but on the other hand, the percentage of the cytokine 
production measures the quality of the cells to mount each or certain sets of cytokines.  
Taken all of the results together, it can be concluded that the multifunctional 
CD4+ T-cells have more robust responses to stimulants especially in the young 
population when compared to the old, which demonstrate a higher potential of cells in the 
pre-infected young population to mount sets of cytokines associated with better outcomes 
of HIV/SIV infection.  
 Proliferative capacity of CD4+ T cells was also observed in this study. Low 
proliferative capacity of CD4+ T-cells is associated with the decrease in the number of 
CD4+ T cells, which leads to impairment of immune functions in HIV/SIV infection so 
CD4+ counts is commonly used as one of the predictors of HIV disease (57).  Many 
studies have shown evidences of poor CD4+ T cell proliferative responses following T 
cell receptor stimulation in HIV-infected patients. CD4+ T cell proliferation responses to 
HIV antigens is known to be associated with the control of viral replication at all stages 
of disease (58, 59, 60).  The inability of patient cells to proliferate has been associated 
with decreased production of IL-2 (61) and enhanced susceptibility to apoptosis (62). 
Age-related impairments of the immune activation has been studied in the past and my 
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result on the observation of a higher IL-2 production as well as other multiple cytokine 
secretions from the young population should support my hypothesis that the proliferative 
capacity in the young population will be greater than the old. Here, I investigated cell 
proliferation, measured by expression of the Ki-67 nuclear antigen in CD4+ and 
CD8+ lymphocyte with the subsets of CD4+, CD8+, double positive and double negative, 
upon three different stimulants (Anti-CD3, SIVgag and CMV peptides). Surprisingly, 
older population demonstrated a significantly higher percentage of Ki-67 expression in 
CD4+ T-cells upon stimulation with Anti-CD3 (with the addition of Anti-CD28 and Anti-
CD49d as co-stimulatory molecules). However, the opposite affect was seen in the same 
subset of cells upon SIVgag peptide stimulation, with higher expression of Ki-67 in the 
young population. But no significant differences were seen in the group treated with 
CMV peptides nor the absolute counts in all of the conditions. One possible explanation 
to this phenomenon might be because the immune system of the older monkeys are 
exposed to more antigens leading to the higher count in the memory compartment of the 
immune cells. With more exposure to a variety of antigens and with higher proportion of 
memory cells, this might provide the more opportunity for the older RM to interact with 
the stimulant (Anti-CD3) causing a higher expression of the proliferative marker. Further 
analysis on the compartments of T cells comparing the percentages of CD4+ and CD8+ 
subsets in the young and the old RM was done to support this concept. According to my 
analysis, the older RM had significantly higher percentages of CD4+ effector memory 
and central memory cells as well as CD8+ effector memory cells when compared to the 
young (data not shown). This finding corresponds to previous study by Saule et al which 
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provided evidences for the positive correlation between age and the amount of memory T 
cell compartment. 
However, further study is needed to confirm this phenomenon possibly a study 
into a more detail of the surface marker is necessary to confirm this result and to see if 
there is any up-regulations and down-regulations of certain receptors that are associated 
with HIV/SIV infection. But the result of higher Ki-67 expression (higher proliferative 
capacity) in the young population in CD4+ T cells upon SIVgag stimulation supports my 
hypothesis and these results contribute to the ability of young RM to mount stronger 
response for a protective immunity towards HIV/SIV infection since high proliferative 
capacity suggest the preservation of immune cells and less impairments of immune 
functions. 
Mean fluorescence intensity (MFI) of each cytokine was observed in this study. 
Fluorescence has a property that could potentially be used to generate a signature of cell 
state. In this study, MFI data were used as measurements of cytokine expression by 
individual cells. From my study, most of the significant differences of MFI values 
between the two age groups were seen upon the treatment with SIVgag peptide. 
Significantly higher MFI values were observed mainly in the double cytokine secretion 
(IFN-γ+ IL-2+) of CD4+ subsets in the young population. This result corresponds with 
previous studies on the multifunctional characteristics of T cells and their association 
with protective immune response or an improved control of the virus (26). The 
significantly higher MFI values in the young indicate the ability of the young RMs to 
mount a higher quantity of the cytokine production per cell especially in CD4+ subsets. 
Significant differences of MFI values were also detected upon SIVenv peptide treatment 
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but most of the significant data in this group falls under triple cytokine production in the 
portion of TNF-α production, in CD4+ effector and naïve subsets. However, very few 
significant differences as observed in groups treated with PMA/I, SEB and CMV 
peptides. The fact that we are seeing many significant differences in the MFI of different 
combination of cytokines with a higher degree in the young population shows the greater 
SIV peptide specific response from the product of cross reaction between T cell receptors 
and the peptide in the young population when compared to the old. It also shows that 
each cell from the young has more ability to produce a greater quantity of each cytokine 
upon stimulation with SIV specific peptides. As for the MFI data for Ki-67 expression, 
young population had a significantly higher value than the old in CD8+ T-cells upon 
SIVgag stimulation. Again, the fact that young population had a higher capacity of each 
cell to regulate Ki-67 expression upon SIVgag stimulation provide another evidence for a 
greater ability for the young to mount a protective immune response that is associated 
with a better outcome of HIV/SIV infection when compared to the old RM.  
Since there are multiple variables and parameters to be considered in this study, 
the multivariate data analysis via principal component analysis was used as a method to 
define the important immunological parameters that contribute most to the variance in 
data set, which further led to the identification of the parameters that best discriminate 
between the young and old age groups of RM. The contribution of each parameter to the 
whole data set was defined and plotted on the three-dimensional chart using correlation 
coefficient defining each component in the data.  High correlation values contribute more 
to the data as well as the contribution to the separation of the two groups as shown on the 
three-dimensional graphs.  Some immunological parameters that best discriminate the 
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two age groups were defined upon the application of multivariate analysis of the 
frequency of cytokine production according to the coefficient values (data not shown). 
Immunological parameters that contribute most to the data and aide in the differentiation 
of the young and old upon stimulations include, the frequencies of  
1. CD4+ naïve cells producing IL-2+ TNF-α+ and IFN-γ+ IL-2+ TNF-α + 
2. CD4+ effector cells producing IFN-γ+ IL-2+ TNF-α+  
3. CD4+ central memory cells producing IFN-γ  
4. CD8+ naïve cells producing IFN-γ+ TNFα+ 
5. CD8+ effector cells producing IFN-γ+ TNFα+ 
6. CD8+ effector memory cells producing IFN-γ + TNF-α+   
7. CD8+ central memory cells producing TNF-α and IFN-γ   
Upon multivariate analysis of the absolute cell count of cytokine production 
Immunological parameters that contribute most to the data include, the absolute cell 
count of 
1. CD4+ effector cells producing IL-2+ TNF-α+, IFN-γ+ IL-2+ TNFα+, IFN-γ, and 
TNF-α 
2. CD4+ naïve cells producing IFN-γ+ IL-2+ TNF-α+ and IL-2+ TNF-α+ 
3. CD4+ effector memory cells producing IFN-γ, TNF-α and IL-2 
4. CD4+ central memory cells producing IL-2 and IFN-γ  
5. CD8+ naïve cells producing IFN-γ + TNF-α+ and TNF-α 
6. CD8+ effector memory cells producing IFN-γ+ TNF-α+ and TNF-α, 
7. CD8+ effector cells producing IFN-γ+ TNF-α+ and TNF-α alone, 
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The multivariate data analysis of the Mean Fluorescence Intensity (MFI) shows the 
following immunological parameters that best discriminate between the two age groups: 
1. Fluorescence Intensity of IFN-γ from IFN-γ+ IL-2+ TNF-α, IFN-γ + IL-2+, and 
IFN-γ + TNF-α+ produced by CD4+ central memory cells, and fluorescence 
Intensity of TNF-α and IL-2 from CD4+ central memory cells. 
2. Fluorescence Intensity of IFN-γ from IFN-γ + TNF-α+ produced by CD4+ effector 
memory cells, and fluorescence Intensity of TNF-α from CD4+ effector memory 
cells.  
3. Fluorescence Intensity of IFN-γ from IFN-γ + TNF-α+ produced by CD4+ naïve 
cells. 
4. Fluorescence Intensity of IFN-γ from IFN-γ + TNF-α+, and TNF-α alone produced 
by CD4+ effector cells 
5. Fluorescence Intensity of IL-2 from IFN-γ+ IL-2+ TNF-α+  produced by CD8+ 
effector cells, fluorescence Intensity of TNF-α from  IFN-γ+ IL-2+ TNF-α+ 
produced by CD8+ effector cells and fluorescence Intensity of  IFN-γ  from IFN-γ 
+ TNF-α+ produced by CD8+ effector cells. 
6. Fluorescence Intensity of  IFN-γ from IFN-γ+ TNF-α+, and TNF-α  alone 
produced by CD8+ naive 
 Most of the immunological parameters that have high contribution towards the 
differentiation of the two age groups whether in the analysis of the frequency, absolute 
cell count or MFI are mostly the multiple cytokine production (double and triple-cytokine 
production). These results show that the two age groups of RM have observable 
differences in the production of multiple cytokines or the possession of multifunctional 
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cells, which is known to be one of the factors associated with better outcomes in 
HIV/SIV disease. In addition, according to tables 1-3, the data of this study demonstrate 
that most of the younger group showed significantly higher production of cytokines in 
terms of frequencies, absolute cell count and MFI when compared to the older sample 
group.   
Conclusion 
  
The overall data from this study clearly demonstrated that upon stimulation with 
either mass stimulation of SIV specific antigen, the young population of RM provides 
stronger protective responses in terms of HIV infection. In addition, most of the 
discriminatory immunological factors that best differentiate between the young and the 
old mostly fall into the group of multifunctional cytokine production in various subsets of 
CD4+ and CD8+ T cells, which again is known to provide stronger protective responses 
towards the infection. The data in my study shows immune impairment as aging 
progresses, especially in terms of SIV/HIV-relevant parameters. By studying the 
responses of uninfected RM, it provided us with the information on the potential of the 
cells of this species that are susceptible to the disease just like human. The underlying 
potential to mount greater protective immune responses against SIV in the young can be 
used to confirm the previous studies on the protective immune responses in RM. This 
finding would provide initial evidence to explain age-dependent differences in 
progression patterns. These results might also be beneficial in planning of future 
experiments using the most popular primate model in HIV/AIDS research (the rhesus 
macaque), and providing researchers with information to help them choose proper age 
groups to include in their experiments  
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